MyOme Develops Cross-Ancestry Breast Cancer Polygenic Risk Score, Plans Product Launch — GenomeWeb
June 15, 2022
"NEW YORK – Personalized genomics company MyOme presented data at the recent American Society of Clinical Oncology conference demonstrating its ability to train and validate a cross-ancestry polygenic risk score (caPRS) for breast cancer."